Ernst Geutjes | PhD, Associate

Ernst Geutjes

Ernst has over 10 years of experience in cancer research, oncology drug development and venturing. Ernst holds a PhD in molecular cancer genetics from the Netherlands Cancer Institute (NKI-AvL) after which he continued his career as business developer at the research- and technology organization TNO, where he has a role in spinning-of biotech companies. As associate at Aglaia he is responsible for analysis of investment proposals, scouting of new investment opportunities and offers strategic and operational support to Aglaia’s portfolio companies. He is acting managing director for Sapreme Technologies and board observer for Macrophage Pharma.


Home > Team > Ernst Geutjes

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds